Search
for
Sort by
Research 721–750 of 1000+
- Targeting olfactory receptor OR2AT4: An innovative aptamer-based treatment for hair growth promotion
- Enhanced therapeutic effects of all-trans retinoic acid nanostructured lipid carrier composite gel drug delivery system for alopecia areata
- Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
- Traditional Strategies and Cutting-Edge Technologies Used for Animal Breeding: A Comprehensive Review
- Caffeine as an Active Molecule in Cosmetic Products for Hair Loss: Its Mechanisms of Action in the Context of Hair Physiology and Pathology
- Review of Drug Repositioning in Cancer Therapeutics
- Effectiveness and Safety of Hair Growth Formulation Containing <i>Tectona grandis</i> L.f (Teak) Leaf Extract: A Randomized, Double-Blind, Placebo-Controlled Study on Males with Androgenic Alopecia
- Mendelian randomization study highlights hypothyroidism as a causal determinant of alopecia areata
- Aberrant connective tissue sheath contraction drives premature hair follicle regression by inducing progenitor cell depletion in androgenetic alopecia
- The use of platelet‐rich plasma in wound healing and vitiligo: A systematic review and meta‐analysis
- CRISPR/Cas9-mediated Generation of<i>COL7A1</i>-deficient Keratinocyte Model of Recessive Dystrophic Epidermolysis Bullosa
- Life Sciences Discovery and Technology Highlights
- Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
- Ar/miR-221/IGF-1 Pathway Mediates the Pathogenesis of Androgenetic Alopecia
- Recent advances in treatment for Benign Prostatic Hyperplasia
- A bibliometric and visual analysis of the research status and hotspots of seborrheic dermatitis based on web of science
- The BLMP-1 transcription factor promotes oscillatory gene expression to achieve timely molting
- The Future of Aesthetic Medicine: Patient‐Centered Trends and Technologies with Dr. Face and Dr. Slim
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- A Review on Formulation and Evaluation of Shampoo
- Pepsin Digestion for Proteomic Studies of the Human Hair Shaft
- Amine‐Functionalized Chitosan/dECM Composite Promotes Cutaneous Regeneration and Hair Follicle Activation by Regulating Oxidative Stress and Inflammation
- USE OF TECHNOLOGY OF CRYODESTRUCTION OF PLANT RAW MATERIALS AND STUDY OF THE THERAPEUTIC EFFECTIVENESS OF THE VETERINARY PREPARATION "AKARO SPECTRA" (ANTI-PARASITIC TABLETS FOR DOGS)
- The genetic basis of dermatophytosis skin infection susceptibility
- On the Question of the Diversity and Effectiveness of Therapy Methods for Androgenetic Alopecia
- Overactive Wnt5a signaling disrupts hair follicle polarity during mouse skin development
- Neuroimmunoendocrine circuitry of the ‘brain-skin connection’
- Micro‐RNA‐31 controls hair cycle‐associated changes in gene expression programs of the skin and hair follicle
- Delta Opioid Receptors Presynaptically Regulate Cutaneous Mechanosensory Neuron Input to the Spinal Cord Dorsal Horn